DPRX Insider Trading Activity and SEC Form 4 Filings
DPRX insider trading summary
No open-market insider purchases or sales of Dipexium Pharmaceuticals, Inc. (DPRX) have been reported on SEC Form 4 in the past 12 months.
Latest DPRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 21, 2014 | Jack H Dean | Director | Buy | $27K (3,000 @ $9.00) |
| Mar 18, 2014 | Robert J Deluccia | Executive Chairman | Buy | $25K (2,083 @ $12.00) |
| Mar 18, 2014 | Robert G. Shawah | Chief Accounting Officer | Buy | $6K (500 @ $12.00) |
| Mar 18, 2014 | David Garrett | VP, Finance & Corp. Dev. | Buy | $25K (2,083 @ $12.00) |
| Mar 18, 2014 | David P Luci | President, CEO, Secretary | Buy | $25K (2,083 @ $12.00) |
| Mar 18, 2014 | Christopher J Coughlin | Director | Buy | $25K (2,083 @ $12.00) |
| Mar 18, 2014 | Jack H Dean | Director | Buy | $25K (2,083 @ $12.00) |
| Mar 18, 2014 | Thomas L Harrison | Director | Buy | $24K (2,000 @ $12.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.